Pharmacological Intensification Strategies in Highly Refractory Obsessive-Compulsive Disorder: Evidence Synthesis and...

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Treatment-resistant obsessive-compulsive disorder (TR-OCD) presents significant clinical challenges.
• Current guidelines for TR-OCD include optimized serotonin reuptake inhibitor (SRI) therapy, clomipramine, exposure and response prevention, and antipsychotic augmentation.
• A considerable number of patients do not respond adequately to established treatments, necessitating exploration of alternative strategies.

Purpose of the Study:

• To review pharmacological intensification strategies for TR-OCD.
• To present a case series of patients with highly refractory OCD treated with intensification strategies.
• To evaluate the preliminary efficacy and safety of these advanced treatment approaches.

Main Methods:

• A structured narrative synthesis of existing literature on TR-OCD pharmacological strategies.
• A retrospective observational case series of five patients from a tertiary OCD referral clinic.
• Definition of treatment resistance: failure to achieve ≥35% Y-BOCS reduction after adequate SRI trials and ERP.

Main Results:

• Five intensification strategies were employed: supratherapeutic SSRI dosing, SSRI + mirtazapine, dual SSRI, serotonergic intensification with clozapine, and topiramate augmentation.
• Symptom reduction (Y-BOCS) at 12 weeks ranged from 23% to 36%, with one patient responding, three near-responding, and one showing partial improvement.
• No cases of serotonin toxicity or significant cardiac complications were observed, indicating a manageable safety profile in this small cohort.

Conclusions:

• Carefully monitored pharmacological intensification may be a feasible option for selected TR-OCD patients in specialist care.
• Efficacy and safety require validation through prospective, controlled research.
• Dual SSRI therapy is considered the most experimental and highest-risk serotonergic approach.